Search Follow us

Key contacts

Dean Richardson
Director, Australasia

Regional office - Australia
Level 4
95 Pitt Street
Sydney
NSW 2000
Australia
Tel: +61 (0)2 8249 8342

Regional office - New Zealand
Edison Investment Research (NZ) Ltd
PO Box 10293
Te Rapa
Hamilton
3241
Tel: +61 (0)2 8249 8342

listed companies

Range Resources Nkwe Platinum
MEC Resources Coal of Africa
Syndicated Metals Gold One
Bionomics Allied Gold Mining
Phylogica ADX Energy
Alkane Resources Bellzone Mining
Sumatra Copper & Gold Continental Coal
Gunson Resources RedFlow
Lochard Energy Circadian Technologies
Universal Coal Biotron
See more

Companies with HQs in asia-pacific

Seeing Machines Forterra Trust
Oil & gas Greka Drilling
Bezant Resources G3 Exploration
Baobab Resources Endace
Wynnstay Group PXP Vietnam Fund
Chatham Rock Phosphate Tenon
MMG SeaDragon
Contact Energy Snakk Media
Cue Energy New Zealand Oil & Gas
Rubicon Sky Network Television
See more

Latest research

Covata

Focused on European opportunity

QuickView | Technology | 22/07/2018

With the $2m in funds raised recently, Covata is planning to strengthen its sales and technical resources in Europe, invest in product development and provide general working capital. Management expects the imminent launch of data classification functionality and the Eclipse cloud-based offering should help drive conversion of the sales pipeline.

Bionomics

RESTORE trial completed, data this quarter

Update | Pharmaceutical & healthcare | 18/07/2018

Bionomics announced on 9 July 2018 that it had completed treatment in its 193-patient Phase II clinical study of BNC210 for post-traumatic stress disorder (PTSD). The RESTORE clinical study completed the treatment phase on time and the company stated that it intends to provide topline data by the end of calendar Q318.

ASLAN Pharmaceuticals

ASLAN004 a go for atopic dermatitis

Update | Pharmaceutical & healthcare | 09/07/2018

ASLAN announced in July 2018 that it has received clinical trial authorisation in Singapore to conduct a Phase I study of ASLAN004 for the treatment of atopic dermatitis (AD). The product is a monoclonal antibody targeting interleukin 13 receptor α 1 (IL13Rα1). The Phase I dosing study will consist of a single dose escalation in healthy volunteers and a multiple dose escalation in AD patients.

China Water Affairs Group

FY18 exceeds forecasts

Update | General Industrials | 04/07/2018

Better-than-expected growth in profitability in FY18, a higher than forecast DPS and a favourable market outlook are clearly positive for China Water Affairs (CWA). We forecast continuing growth over the next few years and have raised our valuation to HK$10 per share. At that price, CWA would trade on a forward-looking P/E multiple of 13.1x, a c 15% discount to our group of selected peers.

PetroMatad

Low-cost, high-impact onshore oil exploration

Initiation | Oil & Gas | 04/07/2018

Petro Matad offers investors exposure to a fully funded exploration campaign targeting near-field, low-risk prospects as well as basin opening, high-impact potential. The 2018 two-well programme in blocks IV and V will test the yet to be drilled Baatsagaan and Taats basins in the heart of Mongolia, targeting 570mmbo of mid-case prospective resource. In Block XX, close to existing production, two low-cost wells will test extensions of proven plays in H218. In 2019 drilling returns to the Tugrug Basin…

About

Edison‘s Sydney and Wellington offices opened in 2011 to provide research services to companies listed on Asia-Pacific stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports See more sector reports See more sector reports